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Abstract. The clinical trial process has become a significant type of services that provides huge 
added value to any national economy. Undoubtedly, the primary group of stakeholders in 
clinical trials of medicines is pharmaceutical companies that obtain a product as a result of 
successful clinical trials. However, other groups involved will also obtain materials and 
intangible benefits from the process of clinical trials of medicines. In this context, the authors 
tended to find out: What are considered to be the primary economic benefits of clinical trials 
of medicines in a society with small population? Aim of the research is to analyse economic 
factors of clinical trials of medicines in countries with small population, taking Latvia as an 
example. Object of the research: economic factors of clinical trials of medicines. The principle 
of snowball has been used to make the selection of the participants' survey. The empirical 
analysis and evaluation of economic factors in unique clinical trials of medicines are based on 
the qualitative research method of semi-structured individual (in-depth) interviews. According 
to the survey, the most important economic type of clinical trials of medicinal products in Latvia 
is “socioeconomic factors”, the average index of the factor being 0.82. The most significant 
three categories of the socioeconomic factors are “Access to the latest treatment methods and 
preparations” (Index max 1), “Improved patient care (time used per patient)” (Index 0.87) and 
“Exchange of experience, transfer of knowledge on the most innovative treatment methods” 
(Index 0.86). Society with small population values the primary economic benefits from clinical 
trials of medicines. It can be concluded that the socioeconomic factor is the most significant, 
compared to the direct economic factor and the alternative cost savings factor. 
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Clinical trials of medicinal products are one of the most important parts in 
developing of new medicines. Clinical trials of medicines are research conducted 
with humans for the purpose of developing or testing clinical, pharmacological 
and other pharmacodynamic effects of medicines, identifying side effects caused 
by their use, examining their pharmacokinetics, in order to determine the safety 
and efficacy of medicines(EU Clinical Trials Register, 2020). 
The pharmaceutical industry, by making significant investments in the 
development of new medicines, not only makes huge profits on these investments, 
but also contributes to public health. As shown in recent studies(Yang & Lee, 
2018), the cost of Research and Development (R&D) investment in the 
pharmaceutical industry is increasing and the productivity is stagnant. For this 
reason, the demand for innovation is growing. It is also estimated (DiMasi, 
Grabowski, & Hansen, 2016) that the cost of developing a new drug has increased 
from USD 800 million (in 2000) to USD 2.87 billion (in 2013). 
Introduction of new medicines on the market is only possible after an 
extensive research, involving high risks. On average, it takes 12-13 years to 
market the development new medicines since synthesising the first active 
substance. The cost of a new chemical or biological substance is around EUR 
1.059 billion. Out of 10 000 new synthesised substances, only one or two becomes 
a marketable product (The European Federation of Pharmaceutical Industries and 
Associations, 2020). 
Investment in research and development in the pharmaceutical industry in 
Europe reached more than EUR 35 300 million in 2017. The dominant positions 
of the United State of America (USA) in the R&D market over the past decade 
has led to a significant shift in economic and research activities to this country. 
Moreover, Europe is facing an increasing competition with emerging economies 
such as Brazil and China, so the geographical balance of the pharmaceutical 
market in the research and development area is expected to gradually shift to 
developing countries. Spending on R&D in the pharmaceutical industry in Europe 
has been growing by 3.8% annually since 2014, compared with the USA, where 
this indicator has been growing at a much faster rate of 8.6%. In 2018, the global 
pharmaceutical and biotechnology sector in the R&D field ranked first in 
the world at 15%, compared to the R&D intensity of the general sector. The 
number of employees involved in pharmaceutical R&D in Europe in 2018 was 
about 115 000 (The European Federation of Pharmaceutical Industries and 
Associations, 2020). 
Aim of the research is to analyse economic factors of clinical trials of 
medicines in countries with small population, taking Latvia as an example. Object 
of the research: economic factors of clinical trials of medicines. The principle of 
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snowball has been used to make the selection of the participants' survey. The 
empirical analysis and evaluation of economic factors in unique clinical trials of 
medicines are based on the qualitative research method of semi-structured 
individual (in-depth) interviews. 
 
Characterization of Clinical Trials of Medicines in Latvia 
 
Despite the fact that Latvia's population is small, there is stable increase in 
clinical trials. On average, 67 permits for clinical trials have been issued over the 




Figure 1 Clinical Trials in Latvia (The State Agency of Medicines of Latvia A, 2020; 
The State Agency of Medicines of Latvia B, 2020) 
 
A rapid increase in permits for clinical trials took place in 2004, resulting in 
bigger volumes of clinical trials in 2005 and 2006. Such an increase in clinical 
trials could be attributed to Latvia's accession to the European Union (EU), a very 
good infrastructure, skilled medical professionals and many treatment “naïve” 
patients. 
The permitted clinical trials of medicines by phases are reflected in the 
number of issued permits, as the number of patients increases significantly with 
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Figure 2 Number of Clinical Trials by Phases in Latvia (The State Agency of Medicines of 
Latvia A, 2020; The State Agency of Medicines of Latvia B, 2020) 
 
Since 2009, 24% of all clinical trials of medicines have been the phase II 
research and 72% the phase III research. 
During the last ten years, the biggest number of permitted clinical trials in 
Latvia was in the following sectors: oncology, pulmonology/allergology/ 
physiatrics, psychiatry/neurology, endocrinology, rheumatology, gastroentero-
logy (see Fig. 3).  
 
Figure 3 Clinical Trials of Medicines in Different Sectors of Therapy (The State Agency of 
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The sectoral breakdown of clinical trials of medicines is very similar to the 
world tendencies where oncology is leading in terms of the number of studies.  
There are a lot of publications devoted to clinical trials of medicines (Abdel-
Kader & Jhamb, 2020; Sakamaki et al., 2020; Thiers, Sinskey, & Berndt, 2008), 
including in Latvia (Logviss, Krievins, & Purvina, 2018), but various economic 
aspects of clinical trials are subject to continuous changes (Kramer, J. 
M.;Schulman, 2012; Petitti, 2009; Pinto, Willan, & O’Brien, 2005; Ramsey et al., 
2015). 
According to approximate estimates of PricewaterhouseCoopers, salaries of 
internal and insourced staff constitute 31%, support services (including couriers, 
accommodation, travelling, translations, etc.) – 8%, remuneration of researchers – 
31%, remuneration of sites – 11%, fees of Ethical Committees – 2%, Central 
Clinical Trial Registry – 1%, medical costs (other than drugs, i.e. lab tests, 
scans, etc.) only 2% and other expenses 14%. More than a quarter of revenues 
from clinical trials come as a tax contribution to the state budget (PwC, 2020). 
The most obvious economic factors can be segmented into benefits for state 
and medical institutions. Costs of clinical trials are covered by sponsors – 
medicines for patients, examinations, as well as the work of doctors and 
nurses, etc.  
Structure of payments by clinical research centres includes all three elements 
of the economic factors directly or indirectly. Direct economic factors include 
national charges, both as labour force taxes and corporate taxes, made by 
researchers and Clinical Research Associates (CRA) within the framework of 
clinical trials. In addition, the direct economic effect may include resources that 
are not paid by the state for medicines and bed day costs for medical treatment of 
patients. Socioeconomic factors are also manifested as benefits for medical and 
scientific authorities as deductions for the use of infrastructure and archiving 
services, which are further directed to develop the clinical and scientific base. 
The process of selecting healthcare services is currently being organised in 
accordance with Cabinet Regulation No. 555 adopted on 28 August 2018 
“Procedures for the Organisation and Payment of Health Services” (Cabinet of 
Ministers, 2018). Hospitals are still paid through a combination of “earmarked 
service programs”, Diagnostic Related Groupings (DRGs) and payments 
according to the actual number of bed days (Strizrep & Alaka, 2016). 
Accordingly, fees and charges for bed days take place in accordance with at least 
this regulatory enactment. Archiving and deductions for the use of infrastructure 
are determined in accordance with contracts for the respective clinical trials. The 
bilateral agreements set also salaries of Clinical Research Associates and 
physicians-researchers. 
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In spite of the obvious significance of direct economic factors in clinical 
trials of medicines, other economic factors, which are not of minor importance, 










Figure 4 Economic Factors of Clinical Trials of Medicines (made by the authors) 
 
The provided categories have been grouped according to the following three 
economic factors: direct economic factors, socioeconomic factors and alternative 
cost savings factors (Kalashnikov, 2004; Lin, Sokolov, & Orlov, 2015; Melihov, 
2006). 
 
Material and Methods 
 
Identification of economic factors. Types of economic factors of clinical 
trials of medicines have been identified based on an analysis of scientific and 
practical literature. Three types of economics factors have been identified. 
An empirical research is based on a systemic approach to investigate the 
maximum possible manifestation properties of the object. This increases the 
probability of acquiring general knowledge about the object of research. Every 
type of economic factors of clinical trials, in terms of content, is comprehensive; 
therefore, expert opinion is used to identify and group economic factors of clinical 
trials of medicines. The authors have selected a model that allows evaluating 
economic factors of clinical trials of medicines in fifteen categories: direct 
economic factors (contribution to the state budget; employment opportunities; 
economic incentives for other supportive businesses; additional revenues of 
medical institutions; provision and improvement of medical infrastructure of 
clinical trials), socioeconomic factors (access to the new standards of Good 
Clinical Practice (GCP); access to the latest treatment methods and preparations; 
improved patient care (time used per patient); in-depth patient care after a 
treatment course; access to examinations not available in Latvia; exchange of 
experience, transfer of knowledge on the most innovative treatment methods; 
professional development of researchers and doctors and work experience) and 
alternative cost savings factors (contribution to the national economy (retaining 
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of working capacity and contribution to the Gross Domestic Product (GDP) 
increase); saving of healthcare and social resources; family contribution to the 
national economy (taxes and GDP increase). 
Search strategy. The principle of snowball has been used to make the 
selection of the participants' survey. As participants with information and 
understanding of what clinical trials are and what the economic factors of clinical 
trials are that could provide useful information, we have used snowball sampling 
so that we could set up a network to find each of the next participants in the survey. 
The empirical analysis and evaluation of economic factors in unique clinical trials 
of medicines are based on the qualitative research method of semi-structured 
individual (in-depth) interviews. A content analysis has been used to process the 
resulting data. A method of logical analysis has been used to reflect the 
conclusions of the empirical study. 
Survey groups. A case study method has been selected for the research to 
analyse the activities of several subjects in three groups. This research method can 
be applied in both developing of new scientific knowledge and solving various 
practical situations. Attention is paid to the subtlety and complexity of the 
individual case. Pauls Stradiņš Clinical University Hospital (PSKUS) is the 
second largest clinical university hospital in Latvia, where the biggest number of 
clinical trial research centres in Latvia is attracted. The validity of the choice of 
the case study research method and the research subject is ensured by: 1) PSKUS 
doctors-researchers involved in conducting clinical trials; 2) administrative staff 
ensuring clinical trial processes at PSKUS; 3) CRA that supervises researches at 
PSKUS. Patients are not selected as research subjects because their responses to 
the economic factors of clinical trials are expected to be highly biased and, above 
all, personal benefits from clinical trials will be mentioned as an economic factor. 
In view of the specific niche of clinical trials, random respondents are not included 
in this survey, since the overall understanding of the economic factors of clinical 




Matrix of economic factors. All three groups of respondents have been also 
analysed in the context of the entire group. In total, 23 respondents have 
participated in this research. For confidentiality purposes, respondents have been 
coded and only their codes have been used in the work – Group 1 (A1 – A9), 
Group 2 (B10 – B16), Group 3 (C17 – C23). Each participant in the survey was 
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Table 1 Summary of the Research Results 
 






State  Contribution to the state budget 107 0.36 
Employment opportunities 144 0.48 
Economic stimulus for other supportive businesses 86 0.29 
Medical 
institution 
Additional revenue of medical institutions  137 0.46 
Provision and improvement of medical infrastructure 
of clinical trials 
137 0.46 
Total sum of the codes: 611  









Access to the new standards of Good Clinical Practice 
(GCP)  
212 0.71 
Access to the latest treatment methods and 
preparations  
297 1.00 
Improved patient care (time used per patient)  259 0.87 
In-depth patient care after a treatment course  235 0.79 




Exchange of experience, transfer of knowledge on the 
most innovative treatment methods 
255 0.86 
Professional development of researchers and doctors 
and work experience)  
235 0.79 
Total sum of the codes: 1712  
Average index of the factor 0.82 
Alternative cost savings 
factor  
 
Contribution to the national economy (retaining working 
capacity and contribution to the GDP increase) 
105 0.35 
Saving of healthcare and social resources 118 0.39 
Family contribution to the national economy (taxes and 
GDP increase) 
74 0.25 
Total sum of the codes: 297  
Average index of the factor 0.33 
 
The research has resulted in the creation of matrices that separate types of 
economic factors, categories of economic factors, codes and the weight factor 
(Index). Table 1 summarises the research results (emphasis on the weight factor 
(Index)). First of all, based on the determined code values, the index (weight 
factor) has been calculated for each category of the economic factors where the 
sum of codes for each category is divided by the maximum code of one of the 
categories (e.g. 107/297; 297/297; 74/297, etc.). The maximum code of the 
categories (the sum of answers of each respondent) is the economic factor 
category - "Access to the latest treatment methods and preparations", 297, in total. 
This allows ranking values of the category of economic factors of clinical trials. 
Secondly, this shows the level of significance of each type of the factor, i.e. 
respondents have identified the topic categories as relevant. The significance of 
each type of factors is indicated as the average weight factor (Index). The average 
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weight factor (Index) has been calculated as the average Weight factor (Index) of 
each type of economic factors. 
Characteristics of the categories of economic factors. For each category of 
economic factors, the Weight factor (Index) has been estimated. The most 
important category for identifying economic factors in clinical trials is the 
“Access to the latest treatment methods and preparations” (Index max 1). Next 
most important indexes are the “Improved patient care (time used per patient) - 
0.87, “Exchange of experience, transfer of knowledge on the most innovative 
treatment methods” - 0.86, “In-depth patient care after a treatment course” - 0.79 
and “Professional development of researchers and doctors and work experience” - 
0.79. The index “Access to examinations not available in Latvia” has been 
estimated as 0.73 and “Access to the new standards of Good Clinical Practice 
(GCP)” as 0.71. All estimated weight factors (Indexes) belong to the category of 
socio-economic factors of economic factors, pertaining to both patients and 
researchers. 
Other most important economic factors are direct economic factors. 
Respondents believe that a positive contribution to the economy is the “Medical 
institution” subfactor – “Additional revenue of medical institutions” and 
“Provision and improvement of medical infrastructure of clinical trials” - index 
0.46. Then follows the “Employment opportunities” category of the “State” 
subfactor - 0.48. Weight factor (Index) of “Contribution to the state budget” is 
0.36 and of “Economic stimulus for other supportive businesses” 0.29.  
Weight factor (Index) of “Saving of healthcare and social resources” is 0.39 
and of “Contribution to the national economy (retaining working capacity and 
contribution to the GDP increase)” 0.35. 
The least important economic category in clinical trials is “Family 
contribution to the national economy (taxes and GDP increase)” (Index 0.25).  
Characteristics of types of economic factors. Another important result is the 
total amount of codes in the context of identifying economic factors in clinical 
trials. The interpretation and conceptualisation of the research data have revealed 
that the type of economic factors - “socioeconomic factors” has the biggest sum 
of codes (1712 in total), the average index of the factoris 0.82 The type of 
economic factors - “direct economic factors” has shown 611 in total, the average 
index of the factor is 0.41, while the type of economic factors - “alternative cost 
savings factor” has the smallest sum of codes (297 in total), the average index of 
the factor is 0.33.  
 
Conclusions and Discussion 
 
Taking into account the results of the survey, financial revenue from clinical 
trials is not the most significant economic factor. The respondents believe that 
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exactly socioeconomic factors give primary economic benefits from clinical trials 
of medicines in a society with small population. Certainly not only in countries 
with a small population, the largest beneficiaries of clinical trials are patients, but 
also researchers. Exchange of experience, transfer of knowledge on the most 
innovative treatment methods and professional development of researchers and 
doctors and work experience are two most significant benefits from clinical trials. 
Financial benefits from clinical trials are of great importance to the national 
economy. Its revenue from clinical trials contributes to the development of a more 
rapid scientific research base for medicated institutions. In the form of different 
national taxes and unpaid medicines, even a country with a small population has 
benefited in terms of several million euro. Although the “Alternative cost savings 
factor” is underestimated on the part of the respondents, this factor can be 
considered as having hidden potential in the context of its economic contribution, 
as it cannot be estimated with account of the high probability of the outcome. 
When assessing how a society with a small population evaluates the primary 
economic benefits from clinical trials of medicines, it can be clearly concluded 
that all categories of the surveyed groups believe that the socioeconomic factor is 
the most significant. Patients in clinical trials are overly beneficial because they 
have access to the latest treatment methods and preparations, and patients benefit 
from the improved patient care. The alternative cost savings factor is the least 
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